Allergan to Present New Data at the 2017 American College of Obstetricians and Gynecologists (ACOG) Clinical and Scientific Meeting in San Diego
DUBLIN, May 4, 2017 /PRNewswire/ — Allergan plc (NYSE: AGN), a leading global pharmaceutical company in women’s healthcare, will present new data from its women’s healthcare portfolio, at the annual American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting in San Diego, May 6-9.
The scheduled times (noted in local Pacific Time) of the presentations and room locations at the San Diego Convention Center are as follows:
- “Ulipristal Acetate Treatment of Uterine Fibroids in Black and Obese Women: VENUS I Subgroup Analyses”
- Authors: Simon JA, Catherino W, Blakesley R, Chan A, Sniukiene V, Al-Hendy A
- Presentation #: 28G (ePoster presentation)
- Sunday, May 7, 2017, 10:30 AM – 11:30 AM
- “Disease Burden Among Canadian Women With Symptomatic Uterine Fibroids: Interim Results of CAPTURE”
- Authors: Laberge P, Singh S, Lamontagne A, Vilos G
- Presentation # 1H (ePoster presentation)
- Sunday, May 7, 2017, 1:00 PM – 2:00 PM
- “Four-year efficacy and safety of the levonorgestrel intrauterine system”
- Authors: Thomas M, Chen B, Kede L, Kimble T, Jensen J, Creinin M
- Presentation Number: 11A (ePoster Session A)
- Saturday, May 6th, 11:00 AM-12:00 PM
ABOUT ALLERGAN WOMEN’S HEALTHCARE
Allergan is a leader in women’s health care that is dedicated to developing and commercializing best-in-class pharmaceuticals to improve the health and wellness of women. Allergan takes a holistic and a best-in-class approach to women’s healthcare as it prioritizes educational partnerships with OB/GYNs. The mission of Allergan Women’s HealthCare extends beyond its pharmaceutical products to ensure that all women can make informed decisions about their health and have access to high-quality medications. Allergan is committed to investing in programs that support the education and well-being of all women.
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceuticals, devices and biologic products for patients around the world.
Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women’s health, urology and anti-infective therapeutic categories.
Allergan is an industry leader in Open Science, the Company’s R&D model, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. This approach has led to Allergan building one of the broadest development pipelines in the pharmaceutical industry with 70+ mid-to-late stage pipeline programs in development. Our Company’s success is powered by our more than 16,000 global colleagues’ commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.
With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.
For more information, visit Allergan’s website at www.Allergan.com.
Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan’s current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Allergan’s current expectations depending upon a number of factors affecting Allergan’s business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan’s products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan’s periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan’s Annual Report on Form 10-K for the year ended December 31, 2016. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.
SOURCE: Allergan plc